Imaging · Contrast AgentRegulatory Approvalregulatorymid-term

FDA Accepts Supplement Application for Gadobutrol by Hengrui Pharma

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/12/2026, 12:32:02 AM

Assessment confidence: 60% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's acceptance of Hengrui Pharma's supplemental application for Gadobutrol is a significant regulatory milestone that could strengthen their competitive position in the contrast agent market. Portfolio teams should prepare for potential shifts in market dynamics as established players may respond strategically. Regulatory context from FDA (FDA AP — GADOBUTROL (SUPPL)) supports the near-term read. Assessment grounded in 22 ranked evidence items (7 high-relevance).

Strategic Assessment

Portfolio teams should assess the potential market impact and prepare for competitive responses from other contrast agent manufacturers. The strongest clinical anchor is The Effect of SuJok Application on Dysmenorrhea and Quality of Life in Young People With Primary Dysmenorrhea: (ClinicalTrials.gov), moderate corpus alignment. In Imaging · Contrast Agent, 6 regulatory and 5 competitive items passed relevance filtering for Hengrui Pharma.

Competitive Pressure

The most relevant competitive pressure comes from FDA Approves Supplemental Application for XELJANZ XR by Pfizer (Humanexa Signals) — sponsor/company relevance (pfizer). FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need. This acceptance may enhance Hengrui Pharma's position in the contrast agent market, competing with established players.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — GADOBUTROL (SUPPL) (FDA). Entity match (hengrui pharma). Relevant agencies in corpus: FDA, MHRA. The acceptance of the supplemental application indicates a positive regulatory trajectory, but the final approval and market entry timeline remain critical to assess.

Key Risks

Elevated medium regulatory exposure for Hengrui Pharma could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

This development could lead to increased market share for Hengrui Pharma, impacting revenue streams for existing competitors in the contrast agent space.
Upside for Hengrui Pharma may improve if Rarely reported cases of hepatotoxicity associated with turmeric- and curcuminoid-containing dietary supplements: a comprehensive review by USP. (PubMed) delivers favorable follow-through.
Upside for Hengrui Pharma may improve if Partial Enteral Nutrition as Therapeutic Augmentation of Advanced Pharmacological Therapy in Patients With Active Crohn's Disease (ClinicalTrials.gov) delivers favorable follow-through.
Portfolio teams should assess the potential market impact and prepare for competitive responses from other contrast agent manufacturers.

What Would Change This Assessment

This becomes more urgent if Monitor the timeline for the FDA's review process and any subsequent approvals or market entries.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — GADOBUTROL (SUPPL)
FDAhigh relevance
Entity match (hengrui pharma)
FDA document
View source
FDA AP — GADOBUTROL (ORIG)
FDAhigh relevance
Entity match (gadobutrol)
FDA document
View source
FDA AP — GADOBUTROL (ORIG)
FDAhigh relevance
Entity match (gadobutrol)
FDA document
View source
FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG)
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG)
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
Class 4 Medicines Defect Notification: Brancaster Pharma Limited, Benzylpenicillin benzathine 1.2 Million I.U. and 2.4 Million I.U. powder for suspension for injection, EL(26)A/30
MHRAmedium relevance
Moderate corpus alignment
FDA document
View source

The Effect of SuJok Application on Dysmenorrhea and Quality of Life in Young People With Primary Dysmenorrhea:
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of Urolithin A Supplementation on Glucose Metabolism in Healthy Adults 55 >= Years Old: A Randomized Triple-Masked Controlled Clinical Trial
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Partial Enteral Nutrition as Therapeutic Augmentation of Advanced Pharmacological Therapy in Patients With Active Crohn's Disease
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Phase I Clinical Trial to Evaluate the Pharmacokinetic and Safety of Ammoxetine Hydrochloride Enteric-Coated Tablets in Participants With Mild Hepatic Impairment, Moderate Hepatic Impairment, and No
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Narrow Band Imaging Versus Artificial Intelligence for Colonic Surveillance in Inflammatory Bowel Disease
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Safety, Tolerability and Levodopa Pharmacokinetics Study of Repeated ND0612 in Parkinson's Disease Patients
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

FDA Approves Supplemental Application for XELJANZ XR by Pfizer
Humanexa Signalshigh relevance
Sponsor/company relevance (Pfizer)
U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
Pfizerhigh relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
FDA Accepts BLA for Langlara by Sunshine Lake Pharma
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Approves Supplemental Application for RINVOQ LQ by AbbVie
Humanexa Signalsmedium relevance
Moderate corpus alignment

A 3.6:1 myo-inositol to D-chiro-inositol ratio and antioxidant-based food supplement before IVF improves fertility in women with PCOS: a pilot observational retrospective cohort study.
PubMedhigh relevance
Mechanism alignment (IO )
FDA document
View source
Wedelactone-loaded exosomes for sepsis-induced liver injury: a novel therapeutic strategy.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Rarely reported cases of hepatotoxicity associated with turmeric- and curcuminoid-containing dietary supplements: a comprehensive review by USP.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Selected immunoendocrine and performance adaptations to upper-body plyometric training and β-alanine supplementation in male swimmers.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Insect-based models in pharmaceutical ecotoxicology: a bibliometric and narrative review.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Hengrui Pharma
Gadobutrol

Commercial impact

medium

This development could lead to increased market share for Hengrui Pharma, impacting revenue streams for existing competitors in the contrast agent space.

Regulatory impact

medium

The acceptance of the supplemental application indicates a positive regulatory trajectory, but the final approval and market entry timeline remain critical to assess.

What to watch

Monitor the timeline for the FDA's review process and any subsequent approvals or market entries.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.